Anita Bellail
co-CEO HB Therapeutics, Inc.
Dr. Anita Bellail is the President and Chief Scientific Officer of HB Therapeutics, a biotechnology company pioneering targeted protein degradation strategies to address oncogenic drivers such as KRAS mutants. With over 20 years of experience in the field of protein degradation, Dr. Bellail has led groundbreaking work in the discovery and development of molecular glue degraders and E3 ligase biology. Her leadership at HB Therapeutics is focused on advancing first-in-class therapeutics by harnessing novel degradation mechanisms to tackle previously undruggable targets in cancer.
Seminars
Wednesday 29th October 2025
Uncovering a Dual Molecular Glue Degrader for KRAS Mutants & CRAF: Harnessing Novel E3 Ligase-Mediated Targeted Protein Degradation
12:00 pm
Tuesday 28th October 2025
Uncovering a Dual Molecular Glue Degrader for KRAS Mutants & CRAF: Harnessing Novel E3 Ligase- Mediated Targeted Protein Degradation
3:00 pm
Download the Full Event Guide for Full Session Details.
- Discovery of a novel molecular glue degrader that simultaneously targets oncogenic KRAS mutants and CRAF, revealing a new strategy to disrupt MAPK signaling
- Engagement of a distinct E3 ligase not previously exploited in KRAS degradation, expanding the landscape beyond commonly used ligases like VHL or CRBN
- Demonstration of a dual degradation mechanism that supports the potential for broader therapeutic applications and highlights the power of molecular glues in targeted protein degradation
